PCI-32765DBL3001

• Research type

  Research Study

• Full title

  A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

• IRAS ID

  131052

• Contact name

  Mikayala King

• Contact email

  mikayala.king@uhs.nhs.uk

• Eudract number

  2013-000959-40

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  NCT01855750

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  13/SC/0323

• Date of REC Opinion

  17 Jul 2013

• REC opinion

  Further Information Favourable Opinion